feedback

Course Director

Michael Boeckh, MD
Michael Boeckh, MD

Fred Hutchinson Cancer Research Center
University of Washington
Seattle, Washington

Faculty

Camille Nelson Kotton
Camille Nelson Kotton, MD, FIDSA, FAST

Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Genovefa Papanicolaou
Genovefa Papanicolaou, MD

Memorial Sloan Kettering Cancer Center
Weill Cornell Medical College of Cornell University
New York, New York

Accredited by

Medical Learning Institute, Inc.

Activity Details

Credit Types:CME
Credit Amount:1.5 Credits
Release Date:2017-Nov-03
Expiration Date:2018-Nov-01
Estimated Time for Completion:90 minutes
Registration Required:No
Cost:Free of Charge

Activity Description and Educational Objectives

In this activity, experts discuss the burden of CMV in solid organ transplant and hematopoietic cell transplant recipients, including the limitations of current anti-CMV medications, the mechanism for and clinical implications of CMV infection resistant or refractory to treatment, and the newest data on emerging agents for treatment of CMV infection.

Upon completion of this activity, participants should be better able to:

  • Identify the burden of CMV in solid organ transplant (SOT) and hematopoietic cell transplant (HCT) recipients, recognizing limitations associated with currently available anti-CMV drugs
  • Outline the mechanisms and clinical implications of CMV infection that is resistant or refractory to standard therapy
  • Summarize current clinical trial data related to emerging antiviral drugs for CMV
  • Integrate current evidence and expert recommendations into treatment plans for CMV infection and/or disease in SOT and HCT recipients

Target Audience

This activity has been designed to meet the educational needs of infectious disease specialists and other healthcare professionals involved in managing CMV in transplant recipients.

Requirements for Successful Completion

In order to receive credit, participants must view the activity and complete the post-test and evaluation form. A score of 70% or higher is needed to obtain CME credit. There are no pre-requisites and there is no fee to participate in this activity or to receive CME credit. Statements of Credit are awarded upon successful completion of the post-test and evaluation form.

Media: Enduring Material
Release and Expiration Dates: November 03, 2017 - November 02, 2018
Time to Complete: 90 minutes

Faculty & Disclosure / Conflict of Interest Policy

Before the activity, all faculty and anyone who is in a position to have control over the content of this activity and their spouse/life partner will disclose the existence of any financial interest and/or relationship(s) they might have with any commercial interest producing healthcare goods/services to be discussed during their presentation(s): honoraria, expenses, grants, consulting roles, speakers bureau membership, stock ownership, or other special relationships. Presenters will inform participants of any off-label discussions. All identified conflicts of interest are thoroughly vetted by Medical Learning Institute, Inc. for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.

The associates of Medical Learning Institute, Inc., the accredited provider for this activity, and PVI, PeerView Institute for Medical Education do not have any financial relationships or relationships to products or devices with any commercial interest related to the content of this CME activity during the past 12 months.

Course Director and Moderator

Michael Boeckh, MD, PhD
Member, Vaccine and Infectious Disease Division
Head, Infectious Disease Sciences Program
Fred Hutchinson Cancer Research Center
Professor, Department of Medicine
University of Washington
Seattle, Washington

Michael Boeckh, MD, PhD, has a financial interest/relationship or affiliation in the form of:
Consultant for Artemis; Astellas Pharma US, Inc.; Chimerix; Helocyte, Inc.; Merck & Co., Inc.; Microbiotix, Inc.; Oxford Immunotec Inc.; and Shire.
Grant/Research Support from Astellas Pharma US, Inc.; Chimerix; Merck & Co., Inc.; and Shire.

Michael Boeckh, MD, PhD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: emerging antiviral drugs and other experimental strategies for the management of CMV infection in transplant recipients.

Faculty

Camille Nelson Kotton, MD, FIDSA, FAST
Clinical Director, Transplant and Immunocompromised Host Infectious Diseases
Infectious Diseases Division
Massachusetts General Hospital
Harvard Medical School
Boston, Massachusetts

Camille Nelson Kotton, MD, FIDSA, FAST, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma US, Inc.; Cellestis-Qiagen; Chimerix; Merck & Co., Inc.; Oxford Immunotec; Roche Diagnostics; and Shire.
Grant/Research Support from Oxford Immunotec.
Other Financial or Material Support from F. Hoffmann-La Roche Ltd; Oxford Immunotec; Roche Diagnostics; and Shire in the form of symposium speaker. Serves as an adjudication committee member for: Astellas Pharma US, Inc.; Merck & Co., Inc.; and Shire.

Camille Nelson Kotton, MD, FIDSA, FAST, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: emerging antiviral drugs and other experimental strategies for the management of CMV infection in transplant recipients.

Genovefa Papanicolaou, MD
Attending Physician, Director of Clinical Trials
Infectious Disease Service
Memorial Sloan Kettering Cancer Center
Professor of Medicine
Weill Cornell Medical College of Cornell University
New York, New York

Genovefa Papanicolaou, MD, has a financial interest/relationship or affiliation in the form of:
Consultant for Astellas Pharma US, Inc.; Chimerix; Merck & Co., Inc.; Oxford Immunotec Inc.; and Shire.
Grant/Research Support from Astellas Pharma US, Inc.; Chimerix; and Merck & Co., Inc.

Genovefa Papanicolaou, MD, does intend to discuss either non-FDA-approved or investigational use for the following products/devices: emerging antiviral drugs and other experimental strategies for the management of CMV infection in transplant recipients.

CME Reviewer

Kaushal Patel, MD
Internal Medicine
Camp Hill, Pennsylvania

Kaushal Patel, MD, has no financial interests/relationships or affiliations in relation to this activity.

Medical Director

Kathryn B. Charalambous, PhD
PVI, PeerView Institute for Medical Education

Kathryn B. Charalambous, PhD, has no financial interests/relationships or affiliations in relation to this activity.

Disclaimer

The information provided at this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a healthcare provider relative to diagnostic and treatment options of a specific patient's medical condition. Recommendations for the use of particular therapeutic agents are based on the best available scientific evidence and current clinical guidelines. No bias towards or promotion for any agent discussed in this program should be inferred.

Providership, Credit & Support

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education. The Medical Learning Institute, Inc. is accredited by the ACCME to provide continuing medical education for physicians.

The Medical Learning Institute, Inc. designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Providership

This CME activity is jointly provided by Medical Learning Institute, Inc. and PVI, PeerView Institute for Medical Education.

Support

This educational activity is supported by an independent medical educational grant from Shire.

Disclosure of Unlabeled Use

The faculty of this educational activity may include discussions of products or devices that are not currently labeled for use by the FDA. Faculty members have been advised to disclose to the audience any reference to an unlabeled or investigational use.

No endorsement of unapproved products or uses is made or implied by coverage of these products or uses in our reports. No responsibility is taken for errors or omissions in reports. For approved prescribing information, please consult the manufacturer’s product labeling.

The materials presented here are used with the permission of the authors and/or other sources. These materials do not necessarily reflect the views of PeerView or any of its partners, providers, and/or supporters.

About This CME Activity

PVI, PeerView Institute for Medical Education, and Medical Learning Institute, Inc. are responsible for the selection of this activity’s topics, the preparation of editorial content, and the distribution of this activity. Our activities may contain references to unapproved products or uses of these products in certain jurisdictions. The preparation of PeerView activities is supported by educational grants subject to written agreements that clearly stipulate and enforce the editorial independence of PVI and Medical Learning Institute, Inc.


Copyright © 2000-2017, PeerView

Suggest a CME Activity

Please provide below the URL and description of an activity you would like to add to OpenCME. You are welcome to add activities as often as you like. To prevent spam or other abuse, activities are reviewed by our editorial team before appearing on OpenCME.

OpenCME for Publishers

Please use the form below if you would like to offer your website visitors high-quality CME content by adding the OpenCME Widget to one or more of your pages.

Send Email to a Colleague

To share this activity with one or more colleagues, enter their e-mail addresses below. To include a personal message, simply overwrite the suggested text below.

(So your recipient knows it's from you.)
Enter multiple recipients separated by a space.
Optionally, replace/modify in the box above the message that will be sent to your colleague(s) with a link to download this app.